Riskpilot← Back to searchSign inGet full accessSunstone Life Science Ventures Fund IV K/S
K/SActiveCVR 38778536Nordre Fasanvej 215Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2017— employees
Revenue 2025
—
EBITDA margin
—
-120% vs 2024
Equity ratio
97.7%
Financial strength
Net profit 2025
DKK -40M
-120% vs 2024
| Revenue | — | — |
| EBITDA | DKK -40M | -120% |
| Net profit | DKK -40M | -120% |
| Total assets | DKK 552,8M | +19% |
| Equity | DKK 540,2M | +16% |
| Employees | — | — |
Legal name
Sunstone Life Science Ventures Fund IV K/S
CVR number
38778536
Legal form
Kommanditselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
26. juni 2017
Share capital
DKK 0
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af komplementaren.
Company purpose
Selskabets formål er at generere overskud ved at foretage, overvåge, udvikle og realisere investeringer i mindre og mellemstore, innovative life science virksomheder, enten direkte eller gennem helt eller delvist ejede holdingselskaber.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -13 | -10 | 1.897 | -227 | 97.969 | — | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -13 | -10 | -13.849 | -16.829 | 81.699 | -9.189 | -42.304 | 199.379 | -40.009 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -13 | -10 | -13.849 | -16.829 | 81.699 | -9.189 | -42.304 | 199.379 | -40.009 |
| Net financials | 0 | 0 | -108 | -6 | -92 | -48 | 156 | 234 | 49 |
| Profit before tax | -13 | -10 | -13.957 | -16.835 | 81.607 | -9.237 | -42.148 | 199.613 | -39.960 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -13 | -10 | -13.957 | -16.835 | 81.607 | -9.237 | -42.148 | 199.613 | -39.960 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 25 | 25 | 52.064 | 56.789 | 185.628 | 244.411 | 327.369 | 466.240 | 552.800 |
| Equity | 12 | 2 | 39.356 | 56.188 | 185.492 | 244.278 | 327.200 | 466.136 | 540.218 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 23 | 12.708 | 601 | 136 | 133 | 169 | 104 | 12.582 |
| Total debt | 13 | 23 | 52.064 | 601 | 136 | 133 | 169 | 104 | 12.582 |
EBITDA margin
-4000900000.0%
This company
15.8%
Market median
-25322151999% vs market
20172025
Equity ratio
97.7%
This company
38.2%
Market median
+156% vs market
20172025
Return on equity
-7.4%
This company
18.4%
Market median
-140% vs market
20172025
Net profit margin
-3996000000.0%
This company
8.1%
Market median
-49333333433% vs market
20172025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172025
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20172025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-06-26 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ML Management | Management | 2019 | — | — |
JP Management | Management | 2017 | — | — |
SL Management | Management | 2017 | — | — |
SV Management | Management | 2017 | — | — |
CA Management | Management | 2017 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2019 | |
VÆKSTFONDEN | Company | 20.0% | 20.0% | 2020 |
Dansk Vækstkapital II K/S | Company | 15.0% | 15.0% | 2019 |
Novo Holdings A/S | Company | 10.0% | 10.0% | 2020 |
Sunstone LSV Special Limited Partner IV ApS | Company | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Sunstone Life Science Ventures Fund IV K/S Board members of Sunstone Life Science Ventures Fund IV K/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Merete Lundbye Møller | Management | 0 companies |
| James Peter Arthur Benson | Management | 0 companies |
| Søren Lemonius | Management | 0 companies |
| Sten Verland | Management | 0 companies |
| Claus Asbjørn Andersson | Management | 0 companies |